Astrid Blom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Astrid Blom has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Philippe Saiag
Dermatology Department, Ambroise Par e Hospital, APHP, Versailles University -Paris-Saclay, Boulogne-Billancourt, France
3 shared publications - Anissa Roger
Department of General and Oncologic Dermatology Ambroise‐Paré Hospital, AP‐HP Boulogne‐Billancourt France
2 shared publications - Anne Tallet
Platform of Somatic Tumor Molecular Genetics Université de Tours, Centre Hospitalier Universitaire de Tours Tours France
2 shared publications - Antoine Touzé
UMR 1282, Université François Rabelais/INRA, Tours, France
2 shared publications - Charlée Nardin
Departement of Dermatology, Centre Hospitalier Universitaire de Besançon , Besançon
2 shared publications - Christine Longvert
Dermatologie générale et oncologique, hôpital Ambroise-Paré, AP–HP, Boulogne-Billancourt, France
2 shared publications
Latest Publications
- 8 April 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (10) , 1937-1946.e7
Distinct Regulation of EZH2 and its Repressive H3K27me3 Mark in Polyomavirus-Positive and -Negative Merkel Cell Carcinoma
- 8 April 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (10) , 1937-1946.e7
Distinct Regulation of EZH2 and its Repressive H3K27me3 Mark in Polyomavirus-Positive and -Negative Merkel Cell Carcinoma
- 1 March 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (3) , 516-527
Merkel Cell Polyomavirus‒Negative Merkel Cell Carcinoma Originating from In Situ Squamous Cell Carcinoma: A Keratinocytic Tumor with Neuroendocrine Differentiation
- 1 March 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (3) , 516-527
Merkel Cell Polyomavirus‒Negative Merkel Cell Carcinoma Originating from In Situ Squamous Cell Carcinoma: A Keratinocytic Tumor with Neuroendocrine Differentiation
- Open Access
- 23 November 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (3) , E164-E166
Impact of the French COVID‐19 pandemic lockdown on newly diagnosed melanoma delay and severity
- 23 November 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (3) , E164-E166
Open AccessImpact of the French COVID‐19 pandemic lockdown on newly diagnosed melanoma delay and severity
- Open Access
- 28 September 2021
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 7 (5) , 615-624
Cutaneous toxicities from targeted therapies used in oncology: Literature review of clinical presentation and management
• Cutaneous toxicities are frequent with targeted therapies. • Managing cutaneous toxicities is critical for life-saving treatment continuation. • Dermatologists can provide a key input in preventing and managing these toxicities.
- 28 September 2021
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 7 (5) , 615-624
Open AccessCutaneous toxicities from targeted therapies used in oncology: Literature review of clinical presentation and management
• Cutaneous toxicities are frequent with targeted therapies. • Managing cutaneous toxicities is critical for life-saving treatment continuation. • Dermatologists can provide a key input in preventing and managing these toxicities.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e21008
Efficacy of combined hypofractionated radiotherapy and anti-PD-1 monotherapy in patients with melanoma.
E21008 Background: Information on the role and type of radiotherapy in melanoma pts treated with anti-PD1 is limited. We report a cohort of advanced melanoma pts having received simultaneous hypofractionated radiotherapy and anti-PD-1 monotherapy. Methods: Database search in the prospective database of a referral center with standardized radiotherapy procedures for all pts having received both treatments between 1/1/15-30/6/16. Radiologists performed independent tumor evaluations (RECIST 1.1) every 3 m, both on radiated and non-radiated lesions. Results: 25 pts with inoperable AJCC stage 3-4 melanoma, mean age 60.5 Y. Anti-PD-1 monotherapy was first systemic treatment in only 40% of pts. Median follow-up after onset of anti-PD-1 therapy (83% nivolumab, 17% pembrolizumab) was 13.3 m, with 48% of pts still alive at last follow-up. Radiotherapy was performed either early (within first 3 m of PD-1 blockade) in pts with rapidly progressing symptomatic lesion(s) (60% of pts) or late ( > 3 m) in pts with slow progression or dissociated response (40% of pts). It consisted of 1 weekly radiation during 4-5 w (84% of pts), or 1 gammaknife radiation for cerebral mets (16% of pts). Median delay between onset of PD-1 blockade and radiotherapy was 1.8 m (range 0.5-11 m). For radiated lesions, rates of complete (CR), partial (PR) responses, stabilization (S) or progression (P) were 24%, 8%, 44%, and 28%, respectively. For non-radiated lesions (84% of pts), rates of CR, PR, S, and P were 29%, 19%, 19%, and 33%, respectively. Among pts radiated late for insufficient response to anti-PD-1 monotherapy, CR or PR in non-radiated lesions (i.e. abscopal response) was observed in 56% of pts. Anti-PD-1 therapy could be discontinued in 4 pts with CR, without relapse to date. No unusual adverse event was recorded. Conclusions: Hypofractionated radiotherapy may enhance anti-PD1 monotherapy efficacy in difficult-to-treat pts. Controlled studies are needed.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e21008
Efficacy of combined hypofractionated radiotherapy and anti-PD-1 monotherapy in patients with melanoma.
E21008 Background: Information on the role and type of radiotherapy in melanoma pts treated with anti-PD1 is limited. We report a cohort of advanced melanoma pts having received simultaneous hypofractionated radiotherapy and anti-PD-1 monotherapy. Methods: Database search in the prospective database of a referral center with standardized radiotherapy procedures for all pts having received both treatments between 1/1/15-30/6/16. Radiologists performed independent tumor evaluations (RECIST 1.1) every 3 m, both on radiated and non-radiated lesions. Results: 25 pts with inoperable AJCC stage 3-4 melanoma, mean age 60.5 Y. Anti-PD-1 monotherapy was first systemic treatment in only 40% of pts. Median follow-up after onset of anti-PD-1 therapy (83% nivolumab, 17% pembrolizumab) was 13.3 m, with 48% of pts still alive at last follow-up. Radiotherapy was performed either early (within first 3 m of PD-1 blockade) in pts with rapidly progressing symptomatic lesion(s) (60% of pts) or late ( > 3 m) in pts with slow progression or dissociated response (40% of pts). It consisted of 1 weekly radiation during 4-5 w (84% of pts), or 1 gammaknife radiation for cerebral mets (16% of pts). Median delay between onset of PD-1 blockade and radiotherapy was 1.8 m (range 0.5-11 m). For radiated lesions, rates of complete (CR), partial (PR) responses, stabilization (S) or progression (P) were 24%, 8%, 44%, and 28%, respectively. For non-radiated lesions (84% of pts), rates of CR, PR, S, and P were 29%, 19%, 19%, and 33%, respectively. Among pts radiated late for insufficient response to anti-PD-1 monotherapy, CR or PR in non-radiated lesions (i.e. abscopal response) was observed in 56% of pts. Anti-PD-1 therapy could be discontinued in 4 pts with CR, without relapse to date. No unusual adverse event was recorded. Conclusions: Hypofractionated radiotherapy may enhance anti-PD1 monotherapy efficacy in difficult-to-treat pts. Controlled studies are needed.